|Mr. Richard A. Gonzalez||Chairman & CEO||6.95M||N/A||1954|
|Mr. Robert A. Michael||President & COO||4M||N/A||1970|
|Mr. Scott T. Reents||Executive VP & CFO||2.97M||N/A||1968|
|Dr. Azita Saleki-Gerhardt Ph.D.||Executive VP & COO||2.58M||N/A||1963|
|Mr. Jeffrey Ryan Stewart||Executive VP & Chief Commercial Officer||2.98M||2.78M||1969|
|Dr. Thomas J. Hudson M.D.||Senior VP of Research & Development and Chief Scientific Officer||N/A||N/A||1962|
|Ms. Elizabeth Shea||Senior Vice President of Investor Relations||N/A||N/A||N/A|
|Mr. Sanjay Narayan||VP, Chief Ethics & Compliance Officer||N/A||N/A||N/A|
|Ms. Tracie Haas||Senior Vice President of Corporate Responsibility, Brand & Communications||N/A||N/A||N/A|
|Mr. Timothy J. Richmond||Executive VP & Chief Human Resources Officer||1.12M||N/A||1966|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 9; Compensation: 6.